Format

Send to

Choose Destination
Clin Exp Metastasis. 2019 Nov 8. doi: 10.1007/s10585-019-10005-2. [Epub ahead of print]

Disparities in the use of stereotactic radiosurgery for the treatment of lung cancer brain metastases: a SEER-Medicare study.

Author information

1
Department of Population and Quantitative Health Sciences, Center for Clinical Investigation, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
2
Case Western Reserve University, Cleveland, OH, USA.
3
Department of Neurosurgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
4
Central Brain Tumor Registry of the United States, Hinsdale, IL, USA.
5
Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Institute for Computational Biology, Case Western Reserve University School of Medicine, 2-526 Wolstein Research Bldg, 2103 Cornell Rd, Cleveland, OH, 44106-7295, USA. jsb42@case.edu.

Abstract

Stereotactic radiosurgery (SRS) is a costly procedure used to irradiate disease tissue while sparing healthy tissue, ideally limiting the side effects of treatment. SRS is frequently used in the setting of lung cancer, which is associated with greater rates of BM, though its cost may lead to potentially inequitable use across patient populations. This study investigates potential disparities in the use of SRS to treat Medicare patients. Surveillance, Epidemiology, and End-Results cancer registry data for patients diagnosed between the years 2010 and 2012 were examined to identify lung cancer patients diagnosed with BM at the same time as their primary cancer (SBM). Medicare claims for SRS were identified; the odds of having SRS claims and hazards of mortality associated with those odds were examined with respect to various clinical and demographic characteristics. Of 74,142 Medicare-enrolled patients diagnosed with lung cancer, 9192 were diagnosed with SBM and 3259 of those patients received SRS. Adjusting for clinical and demographic characteristics, males with SBM had 0.85 times the odds of SRS compared to females with SBM. Black patients and those of other race had significantly lower odds of evidence of SRS compared to WNH patients. SRS may not be delivered equitably among Medicare patients. Males and minority patients may have decreased odds of SRS and worse survival compared to female and WNH patients, respectively.

KEYWORDS:

Lung cancer brain metastases; Observational study; Real-world evidence; SEER-Medicare; Stereotactic radiosurgery

PMID:
31705229
DOI:
10.1007/s10585-019-10005-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center